Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers (WASH-OUT)

Anemia Clinical Trial

— WASH-OUT  

Official title:

Investigation of the Wash-out Effect of Intravenous Iron by Cell Savers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04631679
• Other study ID #: 09-Antl-19
• Status: Completed
• Start date: November 8, 2019
• Est. completion date: April 29, 2021

Study information

• Verified date: September 2021
• Source: University Hospital Muenster
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study is a pilot study, which involves cardiothoracic patients. Patients, who are scheduled for elective cardiosurgical procedure, will be seen in multidisciplinary anesthesia/Patient Blood Management (PBM) clinic and screened for anemia prior to surgery. Anemic patients will eventually be treated with 500mg of ferric carboxymaltose 1 to 4 days prior to surgery. A high blood loss is expected in these procedures (>500ml). Blood is collected and re-transfused to the patient via use of cell savers/ autologous blood restoration. The investigators will examine how fast intravenous ferric carboxymaltose is stored within the iron storage cells of the body, and how much remains within the patients blood at the time point of surgery. Next, the investigators will assess the wash out effect of iron via cell salvage. The hypothesis of this trial is that ferric carboxymaltose is washed out of the collected patient's blood by cell caver usage (Wash-Out Effect).

Description:

Because of the short time frame between iron therapy to procedure in cardiac surgery due to the need to perform cardiac revascularization, the investigators aim to investigate how much of the iron compound ferric carboxymaltose is being stored within the iron storage cells of the human body, and how much remains in the patient's own blood at the time point of surgery. The terminal elimination half-life time of ferric carboxymaltose is known to be approximately 7.1 to 12.1 hours, with peak serum ferritin levels at 48h to 120h after administration. When high blood loss in a surgical procedure is expected, such as in cardiosurgical procedures, the usage of autologous cell salvage, so called "Cell Saver", is considered standard, good practice. The blood that is lost during surgery is collected and after a specified blood separation wash, being retransfused in form of concentrated red blood cells.

This trial aims to examine whether Cell Saver usage might recover high molecular iron complexes such as ferric carboxymaltose lost by bleeding intraoperatively or wash out these molecules.

If amount of lost blood during surgery is too low, that Cell Saver usage would not be possible otherwise, averagely 300ml of blood from the heart-lung machine are added to the cell saver to enable the process of cell saver use.

For each participant, 7 samples will be taken. The samples include patient's blood samples and samples from cell saver compartments (Washing solution, concentrates) as well as from the heart-lung-machine, in detail:

1. arterial patient's blood, preoperative, day of procedure, prior to surgery

2. blood from the heart-lung machine, intraoperative 30 minutes prior to end of use of the heart-lung machine, day of procedure

3. Cell Saver: washed-out compounds, intraoperative, after end of use of heart-lung machine, day of procedure

4. Cell Saver: produced red blood cell concentrate, intra- or postoperative, after end of use of heart-lung machine, day of procedure

5. arterial patient's blood, postoperative, day of procedure

6. venous patient's blood, 3. day postoperative

7. venous patient's blood, 7. day postoperative

By liquid chromatography inductively coupled plasma mass spectrometry (LC-ICP-MS) levels of ferric carboxymaltose are examined

1. in the patient's blood prior to surgery to determine the amount of ferric carboxymaltose within the patients blood prior to surgery, and after a certain time after the intravenous Infusion of ferric carboxymaltose (12-96 hours).

2. pre- and postoperatively and in cell saver compartments. If ferric carboxymaltose is detected in the washing solution of the Cell Saver System and not within the stored red blood cell concentrate, ferric carboxymaltose is washed out by the cell saver.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: April 29, 2021
• Est. primary completion date: April 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• scheduled cardiosurgical procedure such as valve surgery, aortocoronary bypass or both combined within 1-4 days after anesthesiological/PBM clinic

• for Group A: diagnosed anemia (hemoglobin levels below 13g/dL in men and 12g/dL in women) and iron-deficiency (transferrin saturation below 20% or ferritin serum level below 300µg/L), treatment with 500mg of ferric carboxymaltose (FerInject® 50 mg/ml, 10 ml, Vifor Pharma Group, Switzerland).

Exclusion Criteria:

• contraindication for intravenous iron therapy: severe infections, hepatocellular carcinoma, liver metastases, acute severe asthma, a simultaneous oral iron medication, another intravenous iron preparation, iron overload, chronic renal failure with regular intravenous iron substitution during dialysis treatment, age =18 years, pregnancy, lactation and being allergic to iron

• elevated C-reactive protein (CRP) and leukocyte levels (cut-off level for leucocytes for men was <10.9x10^3/µl and for women <12.68x10^3/µl, respectively)

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron Deficiency
• Anemia, Iron-Deficiency
• Iron Deficiency Anemia Treatment

Locations

Country	Name	City	State
Germany	Dept. of Anesthesiology, Intensive Care and Pain Medicine, UKM	Muenster

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Muenster	University of Muenster, Institute of Inorganic and Analytical Chemistry

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ferric Carboxymaltose levels (µg/mL)	Ferric Carboxymaltose levels in samples withdrawn from patient's blood, red blood cell concentrate of Cell Saver, heart-lung machine and washing solution prior to and after surgical procedure (µg/mL-Ferric carboxymaltose/plasma volume)	day of surgery to seven days after surgery
Secondary	Donor red blood cell concentrates	Additional substitution of donor red blood cell concentrates	Beginning till end of surgery
Secondary	Ferritin (ng/ml)	Ferritin levels before intravenous iron supplementation	prior to intravenous iron supplementation
Secondary	Ferritin (ng/ml)	Ferritin levels after intravenous iron supplementation	point of intravenous iron supplementation until surgery
Secondary	Ferritin (ng/ml)	Ferritin levels after intravenous iron supplementation	3 days after surgery
Secondary	Ferritin (ng/ml)	Ferritin levels after intravenous iron supplementation	7 days after surgery
Secondary	Hemoglobin levels (mg/dl)	Delta Hemoglobin levels between prior to IV iron substitution until surgery	prior to intravenous iron supplementation, 1 to 4 days prior to surgery
Secondary	Hemoglobin levels (mg/dl)	Hemoglobin levels after surgery	3 days after surgery
Secondary	Hemoglobin levels (mg/dl)	Hemoglobin levels after surgery	7 days after surgery
Secondary	Intraoperative blood loss (ml)	Blood volume lost while surgical procedure	Beginning till end of surgery
Secondary	Blood volume balance (ml)	Delta of intraoperatively given (infusions, transfusions) and lost (bleeding, withdrawn from heart-lung machine) volumes	Beginning till end of surgery